Exploring Treatment Strategies for Wet AMD and DME

Join a trio of US retina specialists as they review the clinical data of a treatment for Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), as well as a discussion around current treatment paradigms in Wet AMD

Videos From Regeneron

A Treatment Paradigm for Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Phase 3 Clinical Trial Data for EYLEA HD<sup>®</sup> (aflibercept) Injection 8 mg for the Treatment of Wet AMD

Phase 3 Clinical Trial Data for EYLEA HD^® (aflibercept) Injection 8 mg for the Treatment of Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Phase 2/3 Clinical Trial Data for EYLEA HD<sup>®</sup> (aflibercept) Injection 8 mg for the Treatment of DME

Phase 2/3 Clinical Trial Data for EYLEA HD^® (aflibercept) Injection 8 mg for the Treatment of DME

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Resources

Assessing Treatment Paradigms in Wet AMD and DME Therapy in the Age of Extended Dosing Intervals: Parts 1 and 2

View Resource

Assessing Treatment Paradigms in Wet AMD and DME Therapy in the Age of Extended Dosing Intervals: Part 3

View Resource

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.

Visit us online: regeneron.com

Follow Regeneron